Common Contracts
2 similar Joint Research Agreement contracts
Sumitomo Dainippon Pharma and National Institutes of Biomedical Innovation, Health and Nutrition Conclude Joint Research Agreement for Universal Influenza VaccineJoint Research Agreement • April 23rd, 2020
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) and National Institutes of Biomedical Innovation, Health and Nutrition (Headquarters: Ibaraki City, Japan; Director General: Yoshihiro Yoneda; hereafter NIBIOHN) announced today that they have concluded a joint research agreement, aiming at the practical application of a universal influenza vaccine that provides broader protection against most influenza.
N utrition Conclude Joint Research Agreement for Universal Influenza VaccineJoint Research Agreement • April 23rd, 2020
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) and National Institutes of Biomedical Innovation, Health and Nutrition (Headquarters: Ibaraki City, Japan; Director General: Yoshihiro Yoneda; hereafter NIBIOHN) announced today that they have concluded a joint research agreement, aiming at the practical application of a universal influenza vaccine that provides broader protection against most influenza.
